WOŹNIAK, Kinga, GARDIAN-BAJ, Monika, JUNG, Magdalena, HEDESZ, Patryk, JUNG, Maximilian, ŻUK-ŁAPAN, Aleksandra, DORYŃ, Aleksandra, JĘDRAL, Krystian, WŁODARCZYK, Aleksandra, SZCZERBIAK, Alicja and POPCZYŃSKA, Justyna. Alzheimer's Disease - A Comprehensive Review. Journal of Education, Health and Sport. 2024;56:195-209. eISSN 2391-8306.
https://dx.doi.org/10.12775/JEHS.2024.56.013
https://apcz.umk.pl/JEHS/article/view/47975
https://zenodo.org/records/10616659

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 11.01.2024. Revised: 04.02.2024. Accepted: 05.02.2024. Published: 05.02.2024.

Alzheimer's Disease- A Comprehensive Review

Kinga Woźniak, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: kinga966@outlook.com, ORCID: 0009-0007-9802-5888

Monika Gardian-Baj, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: mgardianbaj@gmail.com, ORCID: 0009-0001-6513-9594

Magdalena Jung, University Clinical Hospital in Opole, 26 Wincentego Witosa Avenue, 45-401 Opole, e-mail: magdalenamehel@gmail.com, ORCID 0009-0000-8328-1917

Patryk Hedesz, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: p.hedesz@gmail.com, ORCID: 0009-0006-1886-0916

Maximilian Jung, University Clinical Hospital in Opole, 26 Wincentego Witosa Avenue, 45-401 Opole, e-mail: max.jung@wp.pl, ORCID: 0009-0003-1041-1831

Aleksandra Żuk-Łapan, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: aleksandrazuk11@gmail.com, ORCID: 0009-0009-5580-1001

Aleksandra Doryń, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: aleksandradoryn@gmail.com, ORCID: 0009-0009-1389-5724

Krystian Jędral, Instytut Hematologii i Transfuzjologii 02-776 Warszawa ul. Indiry Gandhi 14, email: kjedral@ihit.waw.pl ORCID: 0009-0005-3467-9458

Aleksandra Włodarczyk, Szpital Miejski Specjalistyczny im. Gabriela Narutowicza w Krakowie, email: olawlo15@wp.pl, ORCID: 0009-0003-5455-9483

Alicja Szczerbiak, Medical University of Warsaw, ul. Żwirki i Wigury 61, 02-091 Warsaw, email: alicjaszczerbiak@gmail.com, ORCID: 0009-0000-5961-4670

Justyna Popczyńska, Medical University of Warsaw, , ul. Żwirki i Wigury 61, 02-091 Warsaw email: jpopczynska@gmail.com ORCID: 0009-0008-7654-923X

Correspondence: kinga966@outlook.com

Abstract

Introduction: Alzheimer's disease (AD) remains a pervasive and challenging neurodegenerative disorder with profound implications for individuals, families, and societies. As the most prevalent cause of dementia globally, AD's prevalence is set to rise significantly in the context of an aging population. This introductory section emphasizes the urgent need for a comprehensive understanding of the disease, encompassing both its molecular intricacies and the socio-economic burden. With age being the primary risk factor, recent research has delved into the complex interplay of genetic predisposition and environmental influences, reshaping our understanding of AD from a multifactorial perspective.

Current State of Knowledge: Advancements in Alzheimer's research have led to a nuanced understanding of its pathology. Traditionally characterized by amyloid-beta plaques and tau tangles, recent insights from neuroimaging and biomarker studies have revealed the intricate nature of these pathologies and their roles in disease progression. Genetic studies, including genome-wide association analyses, have identified susceptibility loci, notably the APOE gene. Simultaneously, environmental factors, such as air pollution and lifestyle choices, are recognized contributors to AD risk. The therapeutic landscape has evolved, with ongoing investigations into anti-amyloid and anti-tau therapies, lifestyle interventions, and precision medicine approaches. The synthesis of these diverse findings highlights the dynamic nature of Alzheimer's research and its potential to shape future treatment modalities.

Summary: In summary, this article provides a comprehensive overview of the current state of knowledge regarding Alzheimer's disease. From understanding its evolving pathology to exploring the interplay of genetic and environmental factors, the multifactorial nature of AD is underscored. The therapeutic landscape is actively advancing, presenting a hopeful outlook for future treatments.

Key words: Alzheimer's disease, Psychiatry, Dementia, Neurodegeneration

1. Introduction:

Alzheimer's disease (AD) poses an escalating challenge in neurodegenerative disorders, becoming the predominant cause of dementia globally and imposing a growing burden on healthcare systems as populations age. With millions affected worldwide, including significant repercussions on individuals and caregivers, the evolving understanding of AD is underscored by ongoing research aimed at unraveling its intricate mechanisms. The disease's impact extends beyond individual suffering, permeating familial and societal structures, particularly as the aging global population anticipates a dramatic rise in AD prevalence. Characterized historically by amyloid-beta plaques and tau tangles, recent advancements, including neuroimaging and biomarker studies, are reshaping the conceptualization of AD, revealing its multifactorial nature. [1,2] While age remains the primary risk factor, genetic predisposition and environmental influences, such as the APOE gene and factors ranging from air pollution to lifestyle choices, contribute layers of complexity to AD's etiology. The therapeutic landscape is witnessing significant strides, encompassing anti-amyloid therapies, innovative approaches targeting tau pathology, and the recognition of lifestyle interventions and precision medicine approaches, reflecting the dynamic nature of AD research. This comprehensive exploration delves into the current state of knowledge surrounding AD, synthesizing findings across diverse research domains, from risk factors to therapeutic strategies, emphasizing the pressing need for continued collaborative efforts in unraveling the mysteries of this complex and devastating neurological disorder. [3,4,5]

2. Pathological Features:

Alzheimer's disease, a neurodegenerative disorder, presents a complex array of pathological features that collectively contribute to its debilitating impact on cognitive function. The most

prominent pathological features include the formation of extracellular beta-amyloid plaques and intracellular neurofibrillary tangles. Beta-amyloid plaques are composed of aggregated beta-amyloid peptides, which are fragments of the amyloid precursor protein. The accumulation of these plaques disrupts normal synaptic function and induces neuroinflammation, further exacerbating neuronal damage. Neurofibrillary tangles, on the other hand, consist mainly of hyperphosphorylated tau protein, leading to the formation of twisted filamentous structures within neurons. This tau pathology is associated with the destabilization of microtubules in the neuronal cytoskeleton, compromising cellular transport and structural integrity.

In addition to plaques and tangles, there is evidence of synaptic and neurotransmitter dysfunction in Alzheimer's disease. Disruptions in neurotransmitter systems, particularly acetylcholine and glutamate, contribute to synaptic failure and impair communication between neurons. Synaptic loss and neuronal damage, particularly in brain regions crucial for memory and cognitive functions such as the hippocampus and neocortex, are prominent features of the disease progression. Furthermore, alterations in the levels of other proteins, such as presenilins and apolipoprotein E (ApoE), are implicated in the pathogenesis of Alzheimer's.

Understanding the intricacies of these pathological features is vital for developing targeted therapeutic interventions aimed at halting or slowing the progression of Alzheimer's disease. [6-9]

3. Risk Factors:

While age remains the primary risk factor for Alzheimer's disease, recent research has unveiled a multifaceted landscape involving a combination of genetic, environmental, and lifestyle factors. Understanding these elements is crucial for elucidating the complex etiology of Alzheimer's disease and developing effective prevention strategies. [4]

3.1 Genetic Factors:

Genetic studies have identified several susceptibility genes associated with Alzheimer's disease, with the apolipoprotein E (APOE) gene being a prominent example. APOE variants, particularly APOE4, are linked to an increased risk of developing Alzheimer's disease. Ongoing research continues to uncover additional genetic factors that may contribute to an individual's susceptibility. [10]

3.2 Environmental Factors:

Environmental factors, including exposure to certain toxins and pollutants, may contribute to the risk of developing Alzheimer's disease. Studies have explored the impact of air pollution, heavy metals, and other environmental stressors on brain health. Understanding these environmental influences is essential for developing strategies to mitigate their effects. [11]

3.3 Cardiovascular Health:

Growing evidence suggests a strong connection between cardiovascular health and the risk of Alzheimer's disease. Conditions such as hypertension, diabetes, and high cholesterol may contribute to vascular changes that impact brain function. Lifestyle modifications and interventions targeting cardiovascular risk factors are increasingly recognized as potential strategies for Alzheimer's disease prevention. [12]

3.4 Education and Cognitive Engagement:

Higher levels of education and lifelong cognitive engagement have been associated with a reduced risk of Alzheimer's disease. Cognitive reserve, built through education and mental stimulation, may confer resilience against the cognitive decline associated with the disease. Understanding the protective role of cognitive engagement offers valuable insights for preventive interventions. [13]

3.5 Social and Lifestyle Factors:

Maintaining an active social life and adopting a healthy lifestyle are linked to a lower risk of Alzheimer's disease. Social engagement, regular physical activity, a balanced diet, and adequate sleep contribute to overall brain health. Exploring the intricate interplay of these factors provides a holistic approach to understanding and mitigating Alzheimer's disease risk. [14]

3.6 Cognitive and Physical Activity:

Engaging in mentally stimulating activities and maintaining physical fitness are associated with a lower risk of Alzheimer's disease. Cognitive and physical activities have been proposed as protective factors that enhance neuroplasticity and promote overall brain resilience against age-related cognitive decline. [15]

The identification and understanding of diverse risk factors for Alzheimer's disease highlight the complexity of its etiology. Integrating genetic, environmental, and lifestyle factors into a comprehensive risk assessment framework is essential for developing personalized prevention strategies and advancing our ability to mitigate the impact of this devastating neurodegenerative disorder.

4. Diagnostic Advances:

Recent breakthroughs in neuroimaging and biomarker research have revolutionized Alzheimer's disease diagnosis. Techniques such as positron emission tomography (PET) scans targeting amyloid and tau proteins, along with cerebrospinal fluid analysis, provide valuable insights into disease progression. These diagnostic tools not only enhance early detection but also offer a means to monitor the efficacy of potential therapeutic interventions, fostering a more personalized approach to patient care. [16-18]

5. Therapeutic Approaches:

While current therapeutic strategies focus on symptom management, the quest for disease-modifying treatments remains ongoing. Anti-amyloid and anti-tau therapies, neuroinflammation modulation, and lifestyle interventions are emerging as promising avenues. Clinical trials targeting various aspects of the disease process provide hope for future breakthroughs, offering the possibility of not only treating symptoms but also addressing the underlying causes of Alzheimer's disease. [19]

5.1 Anti-Amyloid Therapies:

Targeting the amyloid cascade hypothesis, anti-amyloid therapies, such as aducanumab, aim to reduce amyloid-beta plaques. Challenges, including the need for early intervention, are being addressed in ongoing clinical trials. [7,20]

5.2 Anti-Tau Therapies:

Focusing on tau protein abnormalities and neurofibrillary tangles, anti-tau therapies are exploring ways to modulate or clear abnormal tau proteins. [21]

5.3 Neuroinflammation Modulation:

Recognizing the role of neuroinflammation, therapies are being developed to modulate the inflammatory response and mitigate its impact on neuronal health. [22]

5.4 Lifestyle Interventions:

Dietary patterns like the Mediterranean diet, regular exercise, and cognitive training are under investigation as potential preventive and therapeutic measures. [23]

5.5 Combination Therapies:

Combining anti-amyloid, anti-tau, and anti-inflammatory agents, along with lifestyle interventions, is being explored for a comprehensive approach to disease modification. [24]

5.6 Precision Medicine Approaches:

Precision medicine approaches in Alzheimer's disease (AD) represent a paradigm shift in the diagnosis, treatment, and management of this complex neurodegenerative disorder. These approaches aim to tailor medical care to individual variations in genetics, biomarkers, and other personal factors. One key aspect of precision medicine in AD involves genetic profiling, particularly the identification of specific genetic variants such as the APOE ε4 allele, which can influence an individual's risk of developing the disease. Biomarker-based strategies, including cerebrospinal fluid analyses and neuroimaging, play a crucial role in early detection and monitoring disease progression. The integration of these diverse data points enables clinicians to categorize patients into more precise subgroups, allowing for targeted interventions. Recent advancements in pharmacogenomics further support the development of personalized treatment plans, as they take into account an individual's genetic makeup to optimize therapeutic outcomes. While precision medicine in Alzheimer's disease is still evolving, it holds significant promise in advancing our understanding of disease heterogeneity and providing tailored approaches to diagnosis, treatment, and care. [25-28]

The therapeutic landscape for Alzheimer's disease is evolving with diverse approaches under investigation. Collaborative efforts are crucial to advancing treatments that can transform the management of Alzheimer's disease and improve patients' lives. Currently used therapeutic methods are summed up in Table 1.

Table 1. Currently used therapeutic methods

Therapeutic Approach	**Description**	**Examples**	**Ref**
Cholnesterase inhibitors	Increase acetylocholine levels in brain	Donepezil, Rivastigmine, Galantamine	[29]
NMDA Receptor Antagonists	Modulate glutamate activity	Memantine	[30]
Anti-Amyloid Agents	Target and reduce beta-amyloid plaques	Aducanumab, Solanezumab, Gantenerumab	[31]
Tau-Targeted Therapies	Aim to reduce tau protein tangles	LMTX (Leuco-methylthioninium bis(hydromethanesulfonate))	[32]
Anti-Inflamatory Drugs	Reduce inflammation in brain	NSAIDs (Non-steroidal anti-inflammatory drugs)	[33]
Antioxidant Therapy	Combat oxidative stress	Vitamin E, C, Coenzyme Q10	[34]
Cognitive Stimulation	Engage and challenge cognitive abilities	Memory games, puzzles, cognitive training programs	[35]
Physical Exercise	Promote overall health and brain function	Aerobic exercise, strength training, yoga	[36]
Nutritional Interventions	Support brain health through diet	Omega-3 fatty acids, antioxidants, Mediterranean diet	[37]
Music and Art Therapy	Enhance emotional well-being	Listening to music, creating art	[38]

Environmental Modifications	Create supportive living environment	Simplifying surroundings, minimizing distractions	[39]
Support for Caregivers	Provid assistance and emotional support	Support groups, respite care, caregiver education	[40]
Pharmacogenomics	Tailor drug treatments based on genetics	Customizing medication based on individual genetic makeup	[41]

6. Public awareness:

Public awareness of Alzheimer's disease is integral for fostering understanding, reducing stigma, and facilitating early detection, yet studies consistently reveal varied levels of knowledge within different populations. A comprehensive survey conducted in Poland by Skowronek et al. explored public awareness of dementia, uncovering areas where understanding could be enhanced. [42] The results underscored the necessity for targeted educational initiatives to address prevalent misconceptions and to enrich knowledge among the general population. These findings resonate with similar studies conducted in diverse regions, all underscoring the importance of amplifying awareness not only regarding the symptoms and risk factors of Alzheimer's disease but also concerning the available support services for individuals living with Alzheimer's and their caregivers. [43, 44] Global campaigns led by organizations like Alzheimer's Disease International (ADI) and national Alzheimer's associations prove crucial in disseminating accurate information, debunking myths, and encouraging proactive engagement with healthcare services. By fostering a more informed and supportive societal environment, these initiatives aim to address the multifaceted challenges associated with Alzheimer's disease.

7. Summary:

In wrapping up our exploration of Alzheimer's disease, it becomes evident that while progress has been made, there is much more to uncover about this complex brain condition.

Alzheimer's poses significant challenges as our global population ages, impacting individuals, families, and communities. The ongoing research, as highlighted by recent studies and findings, reveals the multifaceted nature of Alzheimer's, challenging previous notions and pushing us to adapt our understanding.

Understanding Alzheimer's goes beyond merely recognizing its symptoms; it involves grasping the intricate web of factors contributing to its onset. Age remains a crucial risk factor, but the interplay between genetic predisposition and environmental influences adds layers of complexity. The identification of susceptibility genes, such as the APOE gene, and the acknowledgment of environmental factors, including lifestyle choices and pollution, point to the need for a comprehensive approach in deciphering Alzheimer's disease.

The therapeutic landscape offers hope, with advancements ranging from traditional drug-based approaches targeting amyloid plaques and tau tangles to innovative strategies encompassing lifestyle interventions and personalized medicine. This dynamic nature of research signals a paradigm shift in how we perceive and treat Alzheimer's. Recognizing the importance of cognitive health, mental stimulation, and physical activity emphasizes the holistic nature of interventions that extend beyond conventional medical treatments.

As we conclude this overview, it is clear that Alzheimer's research is not a finished story but an ongoing narrative, ever-evolving and adapting to new insights. Collaborative efforts across various disciplines remain paramount in unraveling the mysteries of Alzheimer's disease. It is through these collective endeavors that we will continue to refine our understanding, develop effective preventive strategies, and ultimately pave the way for innovative treatments to alleviate the burden of Alzheimer's on individuals and societies alike.

Disclosures: No disclosures.

Financial support: No financial support was received.

Conflict of interest: The authors declare no conflict of interest.

References:

1. 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327-406. doi:10.1002/alz.12328

2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2. doi:10.1016/j.jalz.2012.11.007

3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003

4. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458. doi:10.1038/ng.2802

5. Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179(2):312-339. doi:10.1016/j.cell.2019.09.001

6. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. doi:10.1126/science.1566067

7. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016 Jun 1;8(6):595-608. doi: 10.15252/emmm.201606210.

8. Holtzman DM, Carrillo MC, Hendrix JA, et al. Tau: From research to clinical development. *Alzheimers Dement*. 2016;12(10):1033-1039. doi:10.1016/j.jalz.2016.03.018

9. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A*. 1985;82(12):4245-4249. doi:10.1073/pnas.82.12.4245

10. Bertram L, Tanzi RE. The genetics of Alzheimer's disease. *Prog Mol Biol Transl Sci*. 2012;107:79-100. doi:10.1016/B978-0-12-385883-2.00008-4

11. Cacciottolo M, Wang X, Driscoll I, et al. Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. *Transl Psychiatry*. 2017;7(1):e1022. Published 2017 Jan 31. doi:10.1038/tp.2016.280

12. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american

heart association/american stroke association. *Stroke*. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496

13. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurol*. 2012;11(11):1006-1012. doi:10.1016/S1474-4422(12)70191-6

14. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6

15. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. *Lancet Neurol*. 2004;3(6):343-353. doi:10.1016/S1474-4422(04)00767-7

16. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [published correction appears in Lancet Neurol. 2014 Aug;13(8):757]. *Lancet Neurol*. 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0

17. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

18. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1

19. Perneczky R, Jessen F, Grimmer T, et al. Anti-amyloid antibody therapies in Alzheimer's disease. *Brain*. 2023;146(3):842-849. doi:10.1093/brain/awad005

20. Doody RS, Farlow M, Aisen PS; Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. *N Engl J Med*. 2014;370(15):1460. doi:10.1056/NEJMc1402193

21. Holtzman DM, Carrillo MC, Hendrix JA, et al. Tau: From research to clinical development. *Alzheimers Dement*. 2016;12(10):1033-1039. doi:10.1016/j.jalz.2016.03.018

22. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol*. 2015;14(4):388-405. doi:10.1016/S1474-4422(15)70016-5

23. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5

24. Honig LS, Vellas B, Woodward M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. *N Engl J Med*. 2018;378(4):321-330. doi:10.1056/NEJMoa1705971

25. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. *Alzheimers Dement (N Y)*. 2020;6(1):e12050. Published 2020 Jul 16. doi:10.1002/trc2.12050

26. Hampel, H., O'Bryant, S. E., Durrleman, S., Younesi, E., et al. (2018). A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric, 21(5), 509-518.

27. Kunkle, B. W., Schmidt, M., Klein, H. U., Naj, A. C., Hamilton-Nelson, et al. (2019). Novel Alzheimer disease risk loci and pathways in African American individuals using the African Genome Resources panel: a meta-analysis. JAMA neurology, 76(4), 442-451.

28. Goldman, J. S., & Hahn, S. E. (2016). Clinical implementation of integrated genomic profiling in individuals with Alzheimer's and other neurodegenerative diseases. Molecular Case Studies, 2(6), a001297.

29. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev*. 2006;(1):CD001190. Published 2006 Jan 25. doi:10.1002/14651858.CD001190.pub2

30. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348(14):1333-1341. doi:10.1056/NEJMoa013128

31. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. *Lancet*. 2016;388(10043):505-517. doi:10.1016/S0140-6736(15)01124-1

32. Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet*. 2016;388(10062):2873-2884. doi:10.1016/S0140-6736(16)31275-2

33. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. *JAMA*. 2003;289(21):2819-2826. doi:10.1001/jama.289.21.2819

34. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005;352(23):2379-2388. doi:10.1056/NEJMoa050151

35. Sitzer DI, Twamley EW, Jeste DV. Cognitive training in Alzheimer's disease: a meta-analysis of the literature. *Acta Psychiatr Scand*. 2006;114(2):75-90. doi:10.1111/j.1600-0447.2006.00789.x

36. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial [published correction appears in JAMA. 2009 Jan 21;301(3):276]. *JAMA*. 2008;300(9):1027-1037. doi:10.1001/jama.300.9.1027

37. Eskelinen MH, Ngandu T, Helkala EL, et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. *Int J Geriatr Psychiatry*. 2008;23(7):741-747. doi:10.1002/gps.1969

38. Särkämö T, Tervaniemi M, Laitinen S, et al. Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized controlled study. *Gerontologist*. 2014;54(4):634-650. doi:10.1093/geront/gnt100

39. Gitlin LN, Winter L, Corcoran M, Dennis MP, Schinfeld S, Hauck WW. Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative. *Gerontologist*. 2003;43(4):532-546. doi:10.1093/geront/43.4.532

40. Brodaty H, Donkin M. Family caregivers of people with dementia. *Dialogues Clin Neurosci*. 2009;11(2):217-228. doi:10.31887/DCNS.2009.11.2/hbrodaty

41. Cacabelos R. Pharmacogenomics in Alzheimer's disease. *Methods Mol Biol*. 2008;448:213-357. doi:10.1007/978-1-59745-205-2_10

42. Skowronek, A., Bojkowska-Otrębska, K., & Łabuz-Roszak, B. (2023). Public Knowledge about Dementia in Poland—A Survey Study. Journal of Clinical Medicine, 12(24), 7675. doi: 10.3390/jcm12247675.

43. Alorfi NM. Public Awareness of Alzheimer's Disease: A Cross-Sectional Study from Saudi Arabia. Int J Gen Med. 2022 Sep 28;15:7535-7546. doi: 10.2147/IJGM.S373447. PMID: 36199585; PMCID: PMC9527696.

44. Muglan J, Alkhaldi RM, Alsharif MM, Almuwallad SI, Alotaibi RS. Public Awareness, Knowledge, and Attitude Toward Alzheimer's Disease in Makkah, Saudi Arabia. Cureus. 2023 Nov 19;15(11):e49047. doi: 10.7759/cureus.49047. PMID: 38116357; PMCID: PMC10728572.